ArticleCancer letters2012
HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines.
Article in Cancer letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Molecular Targets of Aptamers in Gastrointestinal Cancers: Cancer Detection, Therapeutic Applications, and Associated Mechanisms.Journal of Cancer · 2023Review
- Targeting HMGA protein inhibits retinoblastoma cell proliferation.RSC advances · 2018Article
- Adenovirus-Mediated Delivery of Decoy Hyper Binding Sites Targeting Oncogenic HMGA1 Reduces Pancreatic and Liver Cancer Cell Viability.Molecular therapy oncolytics · 2018Article
- Article
- HMGA1 expression levels are elevated in pancreatic intraepithelial neoplasia cells in the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer.British journal of cancer · 2017Article
- Development of Phosphorothioate DNA and DNA Thioaptamers.Biomedicines · 2017Review
- Targeting HMGA2 in Retinoblastoma Cells in vitro Using the Aptamer Strategy.Ocular oncology and pathology · 2016Article
- The Architectural Chromatin Factor High Mobility Group A1 Enhances DNA Ligase IV Activity Influencing DNA Repair.PloS one · 2016Article
- RNA-Mediated Regulation of HMGA1 Function.Biomolecules · 2015Review
- MicroRNA let-7 downregulates STAT3 phosphorylation in pancreatic cancer cells by increasing SOCS3 expression.Cancer letters · 2014Article
- The high mobility group A1 molecular switch: turning on cancer - can we turn it off?Expert opinion on therapeutic targets · 2014Review
- Osteopontin-a alters glucose homeostasis in anchorage-independent breast cancer cells.Cancer letters · 2014Article
- Article
- Characterization of the Stoichiometry of HMGA1/DNA Complexes.The open biochemistry journal · 2013Article
- Molecular deregulation induced by silencing of the high mobility group protein A2 gene in retinoblastoma cells.Molecular vision · 2012Article
- Use of cell-SELEX to generate DNA aptamers as molecular probes of HPV-associated cervical cancer cells.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Elevated high mobility group A (HMGA) protein expression in pancreatic cancer cells is correlated with resistance to the chemotherapy agent gemcitabine. Here, we demonstrate use of HMGA-targeted AT-rich phosphorothioate DNA (AT-sDNA) aptamers to suppress HMGA carcinogenic activity. Cell growth of human pancreatic cancer cells (AsPC-1 and Miapaca-2) transfected with AT-sDNA were monitored after treatment with gemcitabine. Significant increases in cell death in AT-sDNA transfected cells compared to non-AT-rich sDNA treated cells were observed in both cell lines. The data indicate the potential use of HMGA targeted DNA aptamers to enhance chemotherapy efficacy in pancreatic cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.